Merck
CN
所有图片(1)

文件

安全信息

P4153

Sigma-Aldrich

Prednisolone 21-hemisuccinate sodium salt

≥90%, powder

登录查看公司和协议定价
所有图片(1)
别名:
Δ1-Hydrocortisone 21-hemisuccinate, 1,4-Pregnadiene-11β,17,21-triol-3,20-dione 21-hemisuccinate, 11β,17α,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-hemisuccinate
线性分子式:
C25H31O8Na
CAS号:
1715-33-9
分子量:
482.50
EC 号:
216-995-1
MDL编号:
MFCD00070045
PubChem化学物质编号:
24898507
NACRES:
NA.77

生物来源

synthetic

无菌性

non-sterile

检测方案

≥90%

形式

powder

颜色

white

溶解性

water: 50 mg/mL, clear, colorless

运输

ambient

储存温度

−20°C

SMILES字符串

[Na].[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)COC(=O)CCC(O)=O

InChI

1S/C25H32O8.Na.H/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30;;/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30);;/t16-,17-,18-,22+,23-,24-,25-;;/m0../s1

InChI key

HLHQSPQPHMOTMP-FKIWUUNWSA-N

正在寻找类似产品? Visit 产品对比指南

象形图

Health hazard
GHS08

警示用语：

Danger

危险声明

H360D

预防措施声明

P201 - P308 + P313

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。

  • 如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。

  • 如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Shin-ichiro Kitajiri et al.
Archives of otolaryngology--head & neck surgery, 128(4), 365-367 (2002-04-03)
To assess the efficacy of corticosteroid therapy for sudden-onset sensorineural hearing loss at lower frequencies. Retrospective, nonrandomized, controlled study. The recovery rate, recovery/improvement rate, and period between the start of therapy and improvement of symptoms were studied in 2 groups:
Y Fujita et al.
Orthodontics & craniofacial research, 11(4), 187-195 (2008-10-28)
To analyse the effects of short-term treatment with etidronate on the glucocorticoid-induced retardation of bone growth and deterioration of bone structure in the prepubertal rat mandible. Fifty 5-week-old male rats were divided into five groups. Etidronate or vehicle treatment (5
Joanna Folwarczna et al.
Pharmacological reports : PR, 63(4), 1040-1049 (2011-10-18)
Glucocorticoid-induced osteoporosis is the most frequently occurring type of secondary osteoporosis. Antagonists of β-adrenergic receptors are now considered to be potential drugs under investigation for osteoporosis. The aim of the present study was to investigate the effects of propranolol, a
Hong Yan et al.
Biological chemistry, 384(8), 1185-1194 (2003-09-17)
Previously we showed that glycation-induced inactivation and loss of antigenicity of enzymes occur simultaneously. Alpha-crystallin, a major structural protein of the mammalian lens, prevents the aggregation of other proteins and protects enzyme function against post-translational modification in vitro. However, it
K Miyanishi et al.
Rheumatology (Oxford, England), 44(3), 332-336 (2004-12-16)
Osteonecrosis (ON) of the femoral head is a devastating complication occurring in patients receiving corticosteroid treatment. This study examined the effect of three corticosteroids on the development of ON in rabbits. Thirty-nine rabbits were injected once intramuscularly with either 25
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门